Recent Updates
Recently added Catalysts
AMRN Positive Sentiment

Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

Key Takeaway: Amarin Corporation plc has announced it will report its third quarter 2025 financial results on October 29, 2025. The company will issue a press release before the market opens and host a conference call with senior management at 8:00 a.m. ET. Participation details for the call and replay options have been provided.
Price reaction · baseline $19.32 (2025-10-14 close) · hit pre-market · clean, no other AMRN news in the window
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Amarin is committed to advancing cardiovascular care.
  • The upcoming financial results may indicate positive growth.
  • The company has a proven track record in efficacy and safety.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
5.6%
average across 2 past catalysts
Cash runway
~78 mo
Minimal dilution risk
Lead asset
AMR101 - /day
Phase 3 · Hypertriglyceridemia

Full Press Release Details

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.
Information on how to participate is as follows.
Access to the live call:
Via telephone: Dial in within the United States: 877-545-0523International dial in: 973-528-0016Access Code: 459510
Via online: A webcast of the call will be available on the Investor Relations section of the Company's website atwww.amarincorp.com.
Access to the replay:
Via telephone: Dial in within the United States: 877-481-4010International dial in: 919-882-2331Access Code: 53008
Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website atwww.amarincorp.com, beginning shortly after the call and available until 3/29/26.

About Amarin

Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact InformationMedia Inquiries:Tegan BerryAmarin Corporation plcPR@amarincorp.com

Frequently Asked Questions

When will Amarin report its Q3 2025 financial results?

Amarin will report its Q3 2025 financial results on October 29, 2025.

What time is the conference call for Q3 2025 results?

The conference call will take place at 8:00 a.m. ET on October 29, 2025.

How can I access the conference call?

You can access the call via telephone or online through Amarin's Investor Relations website.

Will there be a replay of the conference call?

Yes, a replay will be available shortly after the call until March 29, 2026.

Last updated: Oct 15, 2025